View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Market Data
July 8, 2022

Global clinical trials activity decreases 7.6% YoY in Q2 2022

By Carmen

Global clinical trials activity decreased by 7.6% in Q2 2022, when compared with the same quarter in 2021, according to GlobalData.

Industry sponsored trials accounted for a 52.9% share of overall activity in Q2 2022, an increase of 5.5% when compared with Q2 2021.

Non-industry sponsored trials accounted for a 47.1% share of all clinical trials in Q2 2022, marking a decrease of 5.5% when compared with the same period in 2021.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Q2 2022 industry sponsored clinical trials activity by therapy areas

Oncology was the leading therapy area for industry sponsored clinical trials in Q2 2022, accounting for a 31.7% share of all trials.

This was followed by Central Nervous System with a 14.0% share, Infectious Disease with 13.8%, Cardiovascular with 7.6%, and Metabolic Disorders with 7.4%.

In Q2 2021, Oncology led with a 28.0% share, followed by Infectious Disease with 17.7%, Central Nervous System with 12.9%, Metabolic Disorders with 9.2%, and Cardiovascular with 8.5%.

Industry sponsored trials: Q2 2022 vs Q2 2021
Therapy Area Q2 2021 Q2 2022 Activity
Oncology 28.0% 31.7% Increase
Central Nervous System 12.9% 14.0% Increase
Infectious Disease 17.7% 13.8% Decrease
Cardiovascular 8.5% 7.6% Decrease
Metabolic Disorders 9.2% 7.4% Decrease
Gastrointestinal 6.5% 5.7% Decrease
Respiratory 5.5% 5.2% Decrease
Dermatology 4.9% 4.6% Decrease
Immunology 5.1% 4.6% Decrease
Musculoskeletal Disorders 3.7% 3.5% Decrease
Hematological Disorders 2.3% 3.2% Increase
Genito Urinary System And Sex Hormones 2.9% 2.7% Decrease
Ophthalmology 2.2% 2.6% Increase
Genetic Disorders 1.6% 2.5% Increase
Ear Nose Throat Disorders 1.3% 1.3% Decrease
Women’s Health 1.8% 1.3% Decrease
Male Health 1.1% 0.7% Decrease
Hormonal Disorders 0.7% 0.6% Decrease
Mouth and Dental Disorders 0.6% 0.4% Decrease
Nutritional Disorders 0.3% 0.3% Decrease
Non Malignant Disorders 0.1% 0.2% Increase

Most active therapy areas in non-industry sponsored clinical trials

In Q2 2022 the leading therapy area for non-industry sponsored clinical trials was Oncology, accounting for a 25.7% share of all trials.

This was followed Central Nervous System with a 25.6% share, Infectious Disease with 11.4%, Cardiovascular with 9.8%, and Metabolic Disorders with 5.9%.

In Q2 2021, Central Nervous System held the lead in non-industry sponsored clinical trials with a 23.0% share, followed by Oncology with 21.8%, Infectious Disease with 17.4%, Cardiovascular with 9.3%, and Gastrointestinal with 6.8%.

Non-Industry sponsored trials: Q2 2022 vs Q2 2021
Therapy Area Q2 2021 Q2 2022 Activity
Oncology 21.8% 25.7% Increase
Central Nervous System 23.0% 25.6% Increase
Infectious Disease 17.4% 11.4% Decrease
Cardiovascular 9.3% 9.8% Increase
Metabolic Disorders 5.6% 5.9% Increase
Gastrointestinal 6.8% 5.6% Decrease
Musculoskeletal Disorders 4.8% 5.5% Increase
Respiratory 4.6% 4.2% Decrease
Women’s Health 4.3% 3.9% Decrease
Genito Urinary System And Sex Hormones 3.3% 2.7% Decrease
Immunology 3.4% 2.7% Decrease
Dermatology 2.9% 2.5% Decrease
Hematological Disorders 2.7% 2.5% Decrease
Mouth and Dental Disorders 2.0% 2.2% Increase
Ophthalmology 1.8% 1.5% Decrease
Ear Nose Throat Disorders 1.2% 1.3% Increase
Genetic Disorders 0.5% 1.0% Increase
Nutritional Disorders 0.9% 0.9% Decrease
Hormonal Disorders 0.7% 0.5% Decrease
Male Health 0.4% 0.5% Increase
Non Malignant Disorders 0.3% 0.4% Increase

Asia-Pacific region has the most activity for industry sponsored clinical trials

Asia-Pacific was the most active region for industry sponsored clinical trials activity in Q2 2022 with a 52.6% share, compared with 57.5% in Q2 2021.

North America was the second most active region with a 32.0% share in Q2 2022, up from 30.7% in Q2 2021, followed by Europe with a 28.3% share in Q2 2022, up from 27.2% in Q2 2021.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Single country studies held an 85.3% share in industry sponsored clinical trials in Q2 2022, compared with 82.7% in Q2 2021. Multinational trials accounted for 14.7% in Q2 2022, against 17.3% in Q2 2021.

Regional activity for non-industry sponsored clinical trials

Asia-Pacific saw the most non-industry sponsored clinical trial activity in Q2 2022 with a 55.5% share, up from 49.6% in Q2 2021.

North America held the second position with a 21.7% share in Q2 2022, compared with 14.3% in Q2 2021. This was followed by Europe with a 14.1% share in Q2 2022, as against 16.5% in Q2 2021.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Single country studies accounted for 98.7% share of non-industry sponsored clinical trials in Q2 2022, compared with 98.9% in Q2 2021. Multinational trials accounted for a 1.3% share in Q2 2022, up from 1.1% in Q2 2021.

Clinical trials by phase in Q2 2022

Phase II trials outnumbered all other studies with a 37.7% share for industry sponsored trials in Q2 2022, compared with 34.9% in Q2 2021.

The share of Phase I trials stood at 35.8% in Q2 2022, down from 36.2% in Q2 2021. Phase III trials decreased to 16.0% in Q2 2022, compared with 16.1% in Q2 2021, followed by Phase IV trials with a 10.5% share in Q2 2022, against 12.8% in Q2 2021.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

For non-industry sponsored clinical trials, Phase II activity increased to a 48.3% share in Q2 2022, compared with 42.7% in Q2 2021.

Phase IV trials were the second most active with a 21.1% share in Q2 2022, compared with 22.8% in Q2 2021. Phase I trials held a 17.8% share in Q2 2022, against 13.6% in Q2 2021, followed by Phase III trials with a 12.8% share in Q2 2022, over 21.0% in Q2 2021.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Methodology: The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena